1. High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
- Author
-
Jinfeng Wang, Zhe Yang, Han Bai, Lanbo Zhao, Jing Ji, Yadi Bin, Yu Liu, Siyi Zhang, Huilian Hou, and Qiling Li
- Subjects
ACAT2 ,Chemo-response ,Prognosis ,Epithelial ovarian cancer ,Pathology ,RB1-214 - Abstract
Abstract Background Acetyl-CoA acetyltransferase 2 (ACAT2) is a lipid metabolism enzyme and rarely was researched in epithelial ovarian cancer (EOC). Methods ACAT2 expressions were confirmed in two pairs of cell lines (A2780 and A2780/DDP, OVCAR8 and OVCAR8/DDP) from Gene Expression Omnibus database by bioinformatics analysis, and in A2780 and A2780/DDP cell lines by quantitative real-time polymerase chain reaction and western blotting. Tissue samples were stained by immunohistochemistry and scored for ACAT2 expression. The relationships between ACAT2 expression and clinicopathological characteristics were analyzed by χ2 test. The prognosis of ACAT2 was analyzed by the log-rank tests and Cox regression models. Results ACAT2 was remarkably upregulated in the above drug-resistant cell lines by mRNA (all P
- Published
- 2024
- Full Text
- View/download PDF